Heparin therapy for deep venous thrombosis

Area of Science:

• Vascular Medicine
• Hematology

Background:

• Deep venous thrombosis (DVT) is a significant medical condition.
• Previous thrombosis is a common predisposing factor.
• Medical illness, surgery, and trauma also contribute to DVT risk.

Purpose of the Study:

• To evaluate the efficacy of higher-dose heparin therapy in DVT treatment.
• To determine the optimal activated coagulation time (ACT) for heparin therapy.
• To assess the safety profile, including bleeding complications, of intensive heparin treatment.

Main Methods:

• Retrospective review of 156 deep venous thrombosis cases.
• Continuous intravenous heparin therapy administered.
• Activated coagulation time (ACT) used for monitoring heparin dosage.

Main Results:

• Patients with average ACT > 180 seconds showed more rapid recovery and no recurrent DVT or embolism.
• 7 of 65 patients with average ACT < 180 seconds experienced recurrent thrombosis, embolism, or failure to improve.
• Major bleeding was not increased with ACT > 180 seconds, though minor bleeding was higher.

Conclusions:

• Higher-dose heparin therapy, targeting ACT > 180 seconds, is advocated for DVT treatment.
• This approach promotes faster and more complete patient recovery.
• Careful monitoring is essential, especially in specific patient groups like women, the elderly, and post-operative individuals.